Research programme: immuno-oncology therapies - KSQ Therapeutics/Takeda
Latest Information Update: 03 Feb 2021
At a glance
- Originator KSQ Therapeutics; Takeda
- Developer KSQ Therapeutics
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies; T lymphocyte cell therapies
- Mechanism of Action Natural killer cell modulators; Natural killer cell replacements; T lymphocyte modulators; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer